Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03479437 · ClinicalTrials.gov registry record
The TEMPO (Tracing the Effect of the MC4 Pathway in Obesity) Registry
A clinical trial, sponsored by Rhythm Pharmaceuticals.
- Completed
- Registry status
- 303
- Enrollment target
NCT03479437: Completed study, sponsored by Rhythm Pharmaceuticals.
NCT03479437 is a clinical trial that has completed, run by Rhythm Pharmaceuticals. The registered enrollment target is 303 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03479437 has completed, sponsored by Rhythm Pharmaceuticals.
- COMPLETED
- Registry status
- 303 participants
- Enrollment target
Study Summary
A voluntary prospective study that will allow registration and follow-up of individuals with MC4R pathway genetic obesity.
Primary Outcome
Evaluate the quality of life through annual patient and caregiver reported surveys.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 303 participants |
| Start Date | 2018-04-15 |
| Est. Completion | 2020-12-01 |
What the finished NCT03479437 record still lists
NCT03479437 is an observational study that tracks outcomes without assigning an intervention. The registered 303 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT03479437 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03479437 about?
NCT03479437 is a clinical study titled "The TEMPO (Tracing the Effect of the MC4 Pathway in Obesity) Registry". A voluntary prospective study that will allow registration and follow-up of individuals with MC4R pathway genetic obesity.
What is the current status of trial NCT03479437?
This trial is currently completed. The enrollment target is 303 participants. The study started on 2018-04-15. Estimated completion is 2020-12-01.
Who is sponsoring clinical trial NCT03479437?
This trial is sponsored by Rhythm Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05508971 · 303 participants · NA
Treatment of Obstructive Sleep Apnea With Personalized Surgery in Children With Down Syndrome (TOPS-DS)
- NCT04750616 · 304 participants · Phase 2
NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial
- NCT04994717 · 304 participants · Phase 3
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
- NCT06036147 · 304 participants · NA
Concussion Health Improvement Program
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI